Cytokine dysregulation in the post-Q-fever fatigue syndrome

QJM: An International Journal of Medicine

Volumn 91, Issue 8, 1998, Pages 549-560

  Penttila, I A ^a   Harris, R J ^b   Storm, P ^b   Haynes, D ^a   Worswick, D A ^c   Marmion, B P ^a,c,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LYMPHOTOXIN; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; BIOASSAY; CELL CULTURE; CELL STIMULATION; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; COXIELLA BURNETII; CULTURE MEDIUM; CYTOKINE RELEASE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNOSTIMULATION; MALE; MEASLES VIRUS; MONONUCLEAR CELL; PRIORITY JOURNAL; Q FEVER; STATISTICAL ANALYSIS; SYMPTOM;

EID: 0031829106     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/91.8.549     Document Type: Article

References (49)

1. Ormsbee RA, Marmion BP Prevention of Coxiella burnetii infection: vaccines and guidelines for those at risk. In Marrie TJ,ed. Q fever, Vol. 1 The Disease. Boca Raton FL, CRC Press, 1990:226-48.
2. Marmion BP, Ormsbee RA, Kyrkou M, Wright J, Worswick DA, Izzo AA, Esterman A, Feery B, Shapiro RA. Vaccine prophylaxis of abattoir-associated Q fever: 8 years experience in South Australian abattoirs. EpidemiolInfect 1990; 104:275-87.
3. Ackland JR, Worswick DA, Marmion BP. Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q Vax (CSL Ltd), 1985-1990. Med J Aust 1994; 160:704-8.
4. Shannon M. The post Q fever debility & fatigue syndrome: An epidemiological study. MPH Dissertation. University of Adelaide 1993.
5. Marmion BP, Shannon M, Maddocks I, Storm P, Penttila I. Protracted debility and fatigue after Q fever. Lancet 1996; 347:977-8.
6. Ayres JG, Flint N, Smith EG. Chronic fatigue syndrome after acute Q fever. Lancet 1996; 347:978-9.
7. Ayres JG, Flint N, Smith EG, Tunnicliffe WS, Fletcher TJ, Hammond K, Ward D, Marmion BP. Postinfection fatigue syndrome following acute Q fever: follow-up study of patients involved in the 1989 outbreak in the West Midlands. Q J Med 1998; 91:105-23.
8. Andrews PS, Marmion BP. Chronic Q fever 2. Morbid anatomical and bacteriological findings in a patient with endocarditis. Br Med J 1959; 11:983-8
9. Peacock MG, Philip RN, Williams JC, Faulkner RS. Serological evaluation of Q fever in Humans: Enhanced Phase I titers of Immunoglobulin G and A are diagnostic for Q fever endocarditis. Infect Immunity 1983; 41:1089-98.
10. Raoult D, Piquet P, Gallais H, Demicco C, Drancourt M, Casanova P. Coxiella burnetii infection of a vascular prosthesis. N Engl J Med 1986; 315:1358-9.
11. Bronqui P, Dupont HT, Drancourt M, Berland Y, Jerome E, Leport C, Goldstein F, Massip P, Micond M, Bertrand A, Raoult D. Chronic Q fever, ninety two cases from France, including 27 cases without endocarditis. Arch Intern Med 1993; 153:642-8.
12. Khavkin T. Coxiella burnetii infection in prosthetic devices. Rev Infect Dis 1989; 11:835.
13. Ellis ME, Smith CC, Moffat MA. Chronic or fatal Q-fever infection: A review of 16 patients seen in North-East Scotland (1967-80). Q J Med 1983; NSL11 205:54-66.
14. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komoroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121:953-9.
15. Straus SE. Chronic Fatigue Syndrome. New York, Marcel Dekker, 1994.
16. Strober W. Immunological function in chronic fatigue syndrome: In: Straus SE, Ed. Chronic Fatigue Syndrome. New York, Marcel Dekker, 1994:207-37.
17. Kibler R, Lucas DO, Hicks MJ, Poulos BT, Jones JF. Immune function in chronic Epstein-Barr Virus infection. J Clin Immunol 1985; 5:46-54.
18. Chao CC, Janoff EN, Hu S, Thomas K, Gallagher M, Tsang M, Peterson PK. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with chronic fatigue syndrome. Cytokine 1991; 3:292-298.
19. Koster FT, Williams JC, Goodwin IS. Cellular immunity in Q fever: specific lymphocyte unresponsiveness in Q fever endocarditis. J Infect Dis 1985; 152:1283-9.
20. Capo C, Zugun F, Stein A, Tardei G, Lepidi H, Raoult D, Mege J-L. Upregulation of Tumour necrosis factor alpha and Interleukin 1B in Q fever endocarditis. Infect Immunity 1996; 64:1638-42.
21. Amano Ken-Ichi, Williams JC. Sensitivity of Coxiella burnetii peptidoglycan to lysozyme hydrolysis and correlation of sacculus rigidity with peptidoglycan-associated proteins. J Bacteriol 1984; 160:989-93.
22. Izzo AA, Marmion BP. Variation in interferon gamma responses to C. burnetii antigens with lymphocytes from vaccinated or naturally-infected subjects. Clin Exp Immunol 1993; 94:507-15.
23. Worswick D, Marmion BP. Antibody responses in acute and chronic Q fever and in subjects vaccinated against Q fever. J Med Microbiol 1985; 19:281-96.
24. Swanink C, Vercoulen J, Galama J, Roos M, Myaard L, van der Ven-Jongelrijg, de Nijs R, Bleijenberg G, Fennis J, Miedema F, van der Meer J. Lymphocyte subsets, apotosis, and cytokines in patients with chronic fatigue syndrome. J Infect Dis 1996; 173:460-3.
25. Haynes DR, Whitehouse MW, Vernon-Roberts B. The prostaglandin EI analogue, Misoprostol, regulates inflammatory cytokines and immune functions in vitro like natural prostaglandins (1,2,3). Immunology 1992; 76:251-7.
26. Dunn OJ. Multiple comparisons using rank sums. Technometrics 1964; 6:241-52.
27. Izzo A, Marmion BP, Hackstadt T. Analysis of the cells involved in the lymphoproliferative response to Coxiella burnetii antigens. Clin Exp Immunol 1991; 85:98-108.
28. MacDonald KL, Osterholm MT, LeDell KH, White KE, Schenck CH, Chao CC, Persing DH, Johnson RC, Barker JM, Peterson PK. A case control study to assess possible triggers and cofactors in chronic fatigue syndrome. Am J Med 1996; 100:548-54.
29. Chao CC, Gallagher M, Phair J, Peterson PK. Serum neopterin and interleukin 6 levels in chronic fatigue syndrome. J Infect Dis 1990; 162:1412-13.
30. Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP. Hypothalamic-pituitary adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin 6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metabol 1994; 79:934-9.
31. Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S, Isaacs R, Nimer SD. A phase I trial of recombinant human interleukin 6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995; 85:3066-76.
32. Nieken J, Mulder NH, Buter J, Vellenga E, Limburg PC, Piers DA, deVries EGE. Recombinant human IL6 induces rapid and reversible anemia in cancer patients. Blood 1995; 86:900-5.
33. Macs M, Scharpe S, Meltzer HY, Bosnians E, Suy E Calabrese, Cosyns P. Relationships between interleukin 6 activity, acute phase proteins and function of the hypothalmic pituitary adrenal axis in severe depression. Psychiat Res 1992; 49:11-27.
34. Maes M. Evidence for an immune response in major depression. A review and hypotheses. Prog Neuro-Psychopharm Biol Psychiat 1995; 19:11-38.
35. Ur E, White P, Grossman A. Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. Europ Arch Psychiat Clin Neurosci 1992; 241:317-22.
36. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, Greenberg AH. Cytokine-specific central monoamine alterations induced by interleukin 1, 2 and 6. Brain Res 1994; 643:40-9.
37. Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. Reciprocal regulation of the nitric oxide synthase/arginase balance in bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol 1995; 25:1101-4.
38. Syrucek L, Sobeslavsky O, Gutvirth I. Isolation of Coxiella burnetii from human placentas. J Hyg Epidemiol, Microbiol Immunobiol 1958; 2:29-35.
39. McCaul TF, Hackstadt T, Williams JC. Ultrastructural and biological aspects of Coxiella burnetii under physical disruptions. In: Burgdorfer and Anacker, eds. Rickettsiae and rickettsial diseases. Academic Press, 1987:267-80.
40. McCaul TF, Williams JC. Developmental cycle of Coxiella burnetii structure and morphogenesis of vegetative and sporogenic differentiations. J Bacteriol 1991; 147:1063-76.
41. Kordova N, Kovacova E. Appearance of antigens in tissue culture cells inoculated with filterable particles of Coxiella burnetii as revealed by fluorescent antibodies. Acta Virologica 1968; 12:460-3.
42. Ahmed R and Cray D. Immunological memory and protective immunity: Understanding their relation. Science 1996; 272:54-60.
43. Raoult D, Vestris C, Enea M. Isolation of 16 strains of Coxiella burnetii from patients by using a sensitive centrifugation cell culture system and establishment of the strains in HEL cells. J Clin Microbiol 1990; 28:2482-4.
44. Stein A, Raoult D. Lack of phenotype specific gene in human Coxiella burnetii isolates. Microbial Pathogenesis 1993; 00:177-85.
45. Hoover TA, Vodkin MH, Williams JC. A Coxiella burnetii repeated DNA element resembling a bacterial insertion sequence. J Bacteriol 1992; 172:5540-8.
46. Izzo AA, Marmion BP, Worswick DA. Markers of cell mediated immunity after vaccination with an inactivated whole cell Q fever vaccine. J Infect Dis 1988; 157:781-9.
47. Turco J, Thompson HA, Winkler HH. Interferon-y inhibits growth of Coxiella burnetii in mouse fibroblasts. Infection Immunity 1984; 45:781-3.
48. Selden MS, Cameron S. Changing epidemiology of Ross River Virus disease in South Australia. Med J Aust 1996; 165:313-17.
49. White PD, Grover SA, Kangro HO, Thomas JM, Amess J, Clare AW. The validity and reliability of the fatigue syndrome that follows glandular fever. Psychological Med 1995; 25:917-24.